BPG is committed to discovery and dissemination of knowledge
Featured Articles
2/28/2025 11:47:27 AM | Browse: 115 | Download: 80
Publication Name World Journal of Diabetes
Manuscript ID 102390
Country United Kingdom
Received
2024-10-16 18:56
Peer-Review Started
2024-10-18 00:56
To Make the First Decision
Return for Revision
2025-01-08 06:29
Revised
2025-01-08 20:37
Second Decision
2025-01-16 02:35
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief
2025-01-16 02:54
Articles in Press
2025-01-16 02:54
Publication Fee Transferred
Edit the Manuscript by Language Editor
2025-01-19 17:52
Typeset the Manuscript
2025-02-08 01:50
Publish the Manuscript Online
2025-02-28 10:45
ISSN 1948-9358 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology & Metabolism
Manuscript Type Editorial
Article Title Antidiabetic combination therapy and cardiovascular outcomes: An evidence-based approach
Manuscript Source Invited Manuscript
All Author List Vanishri Ganakumar, Cornelius J Fernandez and Joseph M Pappachan
Funding Agency and Grant Number
Corresponding Author Joseph M Pappachan, MD, Professor, Faculty of Science, Manchester Metropolitan University, Lower Ormond Street, Manchester M15 6BH, United Kingdom. drpappachan@yahoo.co.in
Key Words Glucagon-like polypeptide-1 receptor agonists; Cotransporter-2 inhibitors; Cardiovascular disease; Type 2 diabetes mellitus; Cardiovascular outcome trials
Core Tip Glucagon-like polypeptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are important antihyperglycemic medications with cardiovascular (CV) benefits in the form of CV superiority or neutrality, and positive effects on cardiometabolic risk factors. The divergent clinical benefits include significant reductions in hospitalization for heart failure (HF) with SGLT2i, and ischemic stroke and myocardial infarction (MI) with GLP1RA. Zhu et al, in a recent issue of the World Journal of Diabetes, suggest combination therapy with GLP1RA/SGLT2i vs monotherapy with either agent for additional improvement in CV death and recurrent MI, especially in the setting of prior MI or HF.
Publish Date 2025-02-28 10:45
Citation <p>Ganakumar V, Fernandez CJ, Pappachan JM. Antidiabetic combination therapy and cardiovascular outcomes: An evidence-based approach. <i>World J Diabetes</i> 2025; 16(4): 102390</p>
URL https://www.wjgnet.com/1948-9358/full/v16/i4/102390.htm
DOI https://dx.doi.org/10.4239/wjd.v16.i4.102390
Full Article (PDF) WJD-16-102390-with-cover.pdf
Manuscript File 102390_Auto_Edited_013941.docx
Answering Reviewers 102390-answering-reviewers.pdf
Audio Core Tip 102390-audio.m4a
Conflict-of-Interest Disclosure Form 102390-conflict-of-interest-statement.pdf
Copyright License Agreement 102390-copyright-assignment.pdf
Peer-review Report 102390-peer-reviews.pdf
Scientific Misconduct Check 102390-scientific-misconduct-check.png
Scientific Editor Work List 102390-scientific-editor-work-list.pdf
CrossCheck Report 102390-crosscheck-report.png
CrossCheck Report 102390-crosscheck-report.pdf